The 18th CROI: ARV Therapies and Therapeutic Strategies








About the Program

Program Overview

This 1.5-hour Internet symposium will review and discuss the key studies on antiretroviral therapy presented at the 18th Conference on Retroviruses and Opportunistic Infections. The symposium will feature five well-known and recognized thought leaders in the HIV field, with four serving as presenting faculty/discussants and one as program moderator.

This program is certified for CME credit for US physicians by the Postgraduate Institute for Medicine.  

Back to Top   

Target Audience

This activity is intended for physicians, physician assistants, advanced practice nurses, and other health care professionals involved in the treatment and management of patients with HIV infection.

Back to Top

Learning Objectives

After completing this activity, participants should be able to:

  • Explain the key new studies on ARV therapy presented at the 18th CROI; 

  • Outline how to use the advances in clinical management of HIV-positive patients presented and discussed at the 18th CROI to improve patient care;

  • Describe how to apply data presented at the 18th CROI regarding the treatment of ARV-naïve and experienced patients;

  • Construct appropriate ARV regimens for HIV-positive patients;

  • Apply information on newer therapies in therapeutic discussions.

Release Date:  March 10, 2011


Estimated time to complete the CROI 2011 Web Symposium: 1 hour, 30 minutes 

Media: Internet

Back to Top

Course Director and Moderator

John Bartlett, MD
Professor, Johns Hopkins University
School of Medicine
Baltimore, Maryland


José Arribas, MD
Senior Attending Physician, HIV Unit
Hospital de La Paz
Madrid, Spain

David Cooper, MD
Professor, University of New South Wales
Director of The National Centre in Epidemiology & Clinical Research
Sydney, Australia

Joseph Eron, MD
Professor, University of North Carolina
School of Medicine
Chapel Hill, North Carolina

Jürgen Rockstroh, MD
Professor, University of Bonn
Bonn, Germany 

Back to Top  

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the Postgraduate Institute for Medicine and ViralEd, Inc.. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.   

Back to Top

Credit Designation

The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)TM
Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Back to Top

Disclosure of Conflicts of Interest

The Postgraduate Institute for Medicine assesses conflict of interest with its instructors, planners, managers and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Postgraduate Institute for Medicine is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Dr. John Bartlett:

  • Nothing to Disclose

Dr. Jose Arribas:

  • Consulting Fees: Merck & Co.; Abbott; Tibotec; Janssen; Gilead; GlaxoSmithKline; Pfizer; Biogen; Avexa; Bristol-Myers Squibb; ViiV

Dr. David Cooper:

  • Consulting Fees: ViiV; Gilead; Merck & Co.; Tobira; Tibotec; Bristol-Myers Squibb 

Dr. Joseph Eron:

  • Contracted Research: GlaxoSmithKline; Merck & Co.; Taimed
  • Consulting Fees: Bristol-Myers Squibb; Merck & Co.; GlaxoSmithKline/ViiV; Gilead; Tibotec; Virco Laboratories; Tobira; Argos

Dr. Juergen Rockstroh:

  • Contracted Research: Abbott; Merck & Co.; Roche
  • Consulting Fees: Abbott; Bristol-Myers Squibb; BI; Merck & Co.; Roche; GlaxoSmithKline; Pfizer; Gilead; Tibotec; ViiV

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

The following PIM planners and managers: Jan Hixon, RN, BSN, MS, Trace Hutchison, PharmD, Julia Kirkwood, RN, BSN, Samantha Mattiucci, PharmD and Jan Schultz, RN, MSN, CCMEP hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interest related to the content of these activities of any amount during the past 12 months.

Back to Top

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Postgraduate Institute for Medicine (PIM), ViralEd, Inc. and Merck & Co. do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Postgraduate Institute for Medicine, ViralEd, Inc. and Merck & Co. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Back to Top

Instructions for Participation and Credit

There are no fees for participating and receiving credit for this activity.  During the period, March 10, 2011 through March 11, 2012, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; and 3) complete the post-test and evaluation form. 

To answer the questions, click on your selected choice for each answer then proceed to the next question.  We recommend that you print a copy of your answers before you submit them to us.  Once completed, click on the Submit Post-test at the bottom of the page.  Your post-test will automatically be graded.

If you successfully complete the post-test (score of 70% or higher). your certificate will be made available immediately.  Click on View Certificate and print the certificate for your records.  If you received a score of 69% or less, you will receive a message notifying you that you did not pass the post-test.  You may retake the post-test until successful.

You may complete the Post-test on-line at

  • Click on "Find Post-Test/Evaluation by Course" on the navigation menu
  • Search by project ID: 7931
  • Upon successfully completing the Post-test and Evaluation form, your certificate will be made available immediately.

Back to Top  


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Back to Top


 Supported by an educational grant from Merck & Co., Inc.

This coverage is not sanctioned by the conference organizers and is not an official part of the conference proceedings

Prepare to print

Share this page:

Get link code to this page     

Back to Top